IL17RA and psoriasis: Importantly, in psoriasis, the use of the monoclonal antibody Brodalumab, which inhibits IL‐17RA and does not allow IL‐17AA, AF, FF, C, and E to bind, has already been approved; this approach blocks the related signaling pathways and functions to improve psoriasis [39, 57].